Reddit Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Reddit Inc trades at $170.64 (market cap $35.78B), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.4× Reddit Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Reddit Inc nearer its low. Which is the better fit depends on your goals.
| RDDT | VRTX | |
|---|---|---|
Market Cap | $35.78B | $122.33B |
Sector | Media | Health |
52-Week High | $270.71 | $529.59 |
52-Week Low | $121.84 | $366.54 |
Enterprise Value | $33.03B | $117.07B |
Signals from Pluang's Aura AI — not financial advice
Reddit (RDDT) trades at $181.67, up 0.21% today, with a bearish technical signal but strong fundamentals including 91.37% gross margins and recent earnings beats. Analyst consensus is bullish with a $236.89 price target, and institutional interest is rising, as seen with Andra AP fonden's 152.6% stake increase in Q1 2026 (SEC filing, July 21, 2026).
The outlook is positive due to robust revenue growth and AI initiatives, but risks include high valuation multiples and competitive pressures. Near-term focus is on Q2 2026 earnings due July 30, 2026, which could drive volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Reddit Inc. operates a vast network of online communities organized around various interests, known as 'subreddits'. Functioning as a hybrid of a social media platform and a discussion forum, the company generates revenue primarily through advertising and premium subscriptions. Reddit is a major hub for user-generated content, trending news, and viral discussions, and it is a key player in the digital advertising and social media landscape.
Read more on RDDT →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →